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ABSTRACT
This unique case series and review of literature suggests that immune checkpoint 
inhibitors may have clinical activity in neuroendocrine tumors.
Objective: Summarize advances of immuno-oncology in neuroendocrine tumors 
with the help of a case series. 
Design: Case series and review of literature. 
Intervention or Exposure: The patients were treated with immune checkpoint 
inhibitors (pembrolizumab or nivolumab). 
Main Outcome(s) and Measures(s): Life expectancy, quality of life, disease 
progression. 
Results: Maximum durable response of 16 months in one of the patients so far. 
All patients showed improvement in quality of life before disease progression. Two 
out of four are still on therapy. None of the patients experienced immune checkpoint 
inhibitor associated side-effects. All patients had failed standard of care therapy prior 
to the initiation of immune checkpoint inhibitors and were on the verge of hospice.
Conclusions: Immune checkpoint inhibitors have revolutionized cancer 
management and the last 5 years have seen a rapid expansion in the indications for 
this class of drug. Neuroendocrine tumors, unfortunately, have been slow to catch on 
to the immuno-oncology, partly due to difficulties in establishing relevant preclinical 
neuroendocrine tumors models for immune-oncology studies. In this manuscript, we 
review the current status of immunotherapy in neuroendocrine tumors.
INTRODUCTION 
Immune checkpoint inhibitors have rapidly 
advanced in medical oncology. Programmed death-ligand 
1 (PD-L1) is a transmembrane protein that binds to the 
programmed death-1 receptor (PD-1) during immune 
system modulation. The PD-1 receptor is typically 
expressed on cytotoxic T-cells and other immune cells 
while PD-L1 ligand is typically expressed on normal cells 
[31]. Under normal conditions, cells use the PD-1/PD-L1 
interaction as a mechanism of protection against immune 
recognition via inhibiting the action of T-cells thus 
downregulating the immune response such that inactive 
T-cells are exhausted, cease to divide and eventually die 
by programmed cell death or apoptosis [30]. Studies have 
shown that numerous types of tumor cells upregulate the 
expression of PD-L1 as a mechanism to evade the immune 
response [31]. Activated T-cells recognize the PD-L1 
marker on the tumor cell (similar to that of a normal 
cell) and render the cytotoxic T-cell inactive and thus the 
tumor cell escapes the immune cycle for elimination and 
is able to proliferate [31]. Despite a tremendous thrust of 
anti PD-1 and PDL-1 agents, the realm of neuroendocrine 
tumors (NETs) seems to be relatively untouched. This 
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manuscript summarizes current advances of immuno-
oncology in NETs with the help of a case series (Table 1). 
CASE SERIES
Case 1
A 43-year-old female was in her usual state of health 
until about January of 2011 when she developed nausea, 
vomiting and diarrhea. Diarrhea persisted for a couple 
of months and she sought medical help in March 2011. 
Initial conservative management followed by a detailed 
workup done by a gastroenterologist was negative. 
Later, in August 2011 the patient presented to ED with 
complaints of melena. Her CT scan revealed a 9-cm mass 
in the tail of her pancreas with hepatic metastasis. Liver 
biopsy confirmed grade 2 neuroendocrine tumor (Ki-67 
of 6%). The patient was initiated on Sandostatin LAR 
30 mg every 30 days. She noticed rapid improvement 
in her energy level. She subsequently underwent Y90 
radio-embolism of hepatic metastatic disease first in the 
right lobe of the liver followed by the left lobe in the 
months of September and October 2011. The patient had 
a stable course until December 2011, she had another 
episode of GI bleed. In January 2012 she underwent 
partial pancreatectomy, splenectomy, partial gastrectomy 
and left hepatic lobectomy. She was started on sunitinib 
in February 2012, which she had to rapidly discontinue 
within a month due to severe fatigue. She was started on 
capecitabine and temozolomide (CAPTEM) in April 2012. 
The patient tolerated CAPTEM well and started gaining 
weight. An abdominal MRI from May 2013 showed 
mild worsening of some of the hepatic lesions, however 
the rest of the disease was stable. She underwent two 
more doses of Y-90 radioembolism. She was continued 
on long acting somatostatin analog and CAPTEM and 
her subsequent surveillance scan in November 2013 
showed stable disease. A follow-up MRI of the abdomen 
in February 2014 showed mild progression of one of the 
hepatic lesions. She was taken off CAPTEM and started 
on everolimus 10 mg daily. We had to reduce the dose 
of everolimus to 7.5 mg daily due to stomatitis. The 
patient did exceptionally well on the reduced dose of 
everolimus and had stable disease until October 2015, 
at which time she was enrolled into a Phase I clinical 
trial of fosbretabulin for progressive disease in the liver 
and retroperitoneum. The patient got the first dose of 
fosbretabulin in November 2015. She only received three 
cycles of fosbretabulin before she developed disease 
progression in the left supraclavicular and left axillary 
lymph nodes. In February 2016 she was started on off-label 
pembrolizumab. She had stable disease on pembrolizumab 
for 16 months before her disease progressed in axilla 
and breast. Figure 3 shows the current disease burden of 
patient with help of gallium DOTATATE scan. 
Case 2
A 49-year-old woman was in her usual state of 
health until 2014 when she presented with complaints of 
a 6-month history of a non-productive cough, and was 
found to have pneumonia of the right lung. Scans revealed 
a right upper lobe lesion. A subsequent bronchoscopy 
revealed a right upper lobe tumor. On 8/19/2014, the 
patient underwent an upper lobectomy, and pathology 
confirmed the diagnosis of stage III a, typical carcinoid 
(well differentiated NET). Peri-bronchial lymph node (1 
out of 7) was also positive for typical carcinoid. In May 
of 2015, the patient felt a nodule under her skin in her 
left upper back. A biopsy was consistent with a grade 
II well differentiated metastatic neuroendocrine tumor. 
Resection was performed with negative margins, and a 
postoperative CT was negative for additional metastases. 
Patient was surveilled with imaging every 3-4 months. 
An MRI in in fall of 2015 demonstrated progression of 
the disease in the liver and thorax. She was started on 
CAPTEM. Unfortunately, patient progressed after five 
months on CAPTEM. Patient was started on everolimus. 
She progressed after 3 months and was switched to 
daily sunitinib. A CT scan in fall of 2016 demonstrated 
progression of multiple hepatic lesions. She was started on 
off-label nivolumab (240 mg i.v. every 2 weeks). Patient 
had stable disease for 6 months on nivolumab before 
progression and as of now patient has opted hospice. It 
is to be noted that prior to stating nivolumab patient was 
losing weight and reported fatigue. Patient had significant 
Figure 1: Immune checkpoint inhibitor expression on 
tumor and immune cells
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improvement in her energy levels and gained 10-15 
pounds during first 4-5 months on treatment. 
Case 3
A 71-year-old male underwent a distal 
pancreatectomy, splenectomy, and a partial gastric 
resection on 8/12/2012 under the suspicion of the 
presence of a pancreatic tumor. The resection revealed 
a grade II pancreatic NET with 5/18 positive nodes. 
There was evidence of lymphovascular and perineural 
invasion. In February of 2015, he began treatment on 
E2211 clinical trial comparing single agent temozolomide 
to temozolomide + capecitabine, and was randomized 
to receive temozolomide. After progression, he was 
switched to CAPTEM in May of 2015. CAPTEM was 
discontinued in September of 2015 due to progression. He 
was then switched to long acting somatostatin analog. A 
CT scan from 10/20/2015 demonstrated interval hepatic 
metastatic disease progression. He was then started on 
phase I clinical trial of fosbretabulin in December of 2015. 
Fosbretabulin is a vascular disrupting agent currently 
under clinical investigation. Unfortunately, CT scan on 
5/23/2016 showed hepatic progression. He was switched 
to everolimus and progressed after 5 months of therapy. 
He began off-label nivolumab (240 mg i.v. every 2 weeks) 
in December of 2016. At six months, the patient continues 
to tolerate the treatment well and shows radiological stable 
disease. 
Case 4
A 75-year-old woman was initially found to have 
a left lower lung lobe (LUL) lesion during pre-operative 
evaluation for right total knee replacement in December 
2014. CT demonstrated a 1.4cm LUL lesion which 
was biopsied at outside hospital. Biopsy consisted of 2 
FNA which contained neuroendocrine cells positive for 
synaptophysin, chromogranin, CD56, and CK7 as well as 
TTF-1. Ki-67 staining was low. There was no evidence 
of increased mitosis and no necrosis. Morphology and 
immunohistochemistry were compatible with a well-
differentiated neuroendocrine tumor, although the 
precise grade (typical vs atypical carcinoid) could not be 
definitively determined due to limited tissue. Octreotide 
scan done at outside hospital was noted to be positive 
with positivity in the left upper lobe and right mid/
lower pulmonary hilum and focal lesion in the liver. She 
has no evidence of carcinoid syndrome. As it was felt 
that patient has at least a stage IIIB disease with biopsy 
proven positive LN in the contralateral mediastinum. She 
underwent a LUL video assisted thoracoscopy (VATS) 
wedge resection. VATS demonstrated a 1.5 cm moderately 
to poorly differentiated adenocarcinoma with invasion in 
the visceral pleura. Surgical margins were negative and 
tumor was positive for TTF-1. Lymph nodes were negative 
(pT2 N0 M0, stage IA). She subsequently underwent a 
bronchoscopy with an ultrasound-guided biopsy and 
mediastinoscopy. At this procedure, a left lower lobe 
primary carcinoid tumor of the lung was found, but not 
resected at that time since it would require a lobectomy. 
Pathology demonstrated this right lower lobe biopsy 
to show a well-differentiated neuroendocrine tumor. 
A level 7 lymph node on the right was also positive for 
neuroendocrine tumor, well-differentiated. Peritracheal 
nodes were negative.
In May 2016, she has developed a chronic cough. 
Subsequent workup demonstrated progressive disease 
in her chest. Interventional pulmonology and radiation 
oncology recommended SBRT for obstructive lung 
lesion. Post radiation, she was started on somatostatin 
analogs along with everolimus. Gallium DOTATATE 
PET confirmed progressive metastatic disease in thorax 
and abdomen. The patient was started on off-label 
pembrolizumab in June 2017 and her first three monthly 
surveillance CT scan showed stable disease. 
DISCUSSION
One of the hallmarks of a healthy state is 
homeostasis between immune activation and degree of 
inflammatory response. Be it an infectious stimulus or 
tumors, a well-balanced interplay of immune activation 
and subsequent shutdown once the aberrant signal protein 
is eliminated is paramount. An exception to this leads to 
a pathological state. As scientists began to understand the 
Figure 2: Somatic mutational burden in varying tumor 
types
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biology of cancer, it became quite clear that one of the 
mechanisms by which cancer cells evade our immune 
response is with the help of immune checkpoints. As noted 
earlier, most of the known immune checkpoints are in a 
set of cellular receptors or ligands, which once activated 
blunt T cell response against cancer cells. Figure 1 shows 
the mechanism of action of common immune checkpoint 
proteins. This led to development of antibodies towards 
these immune checkpoints with a goal of helping the 
host immune system to re-recognize these tumor cells as 
foreign. 
Traditionally the mutagenic burden of a tumor type 
has been thought to predict activity of immune oncology 
drugs [1]. This hypothesis stems from impressive 
responses noticed in high mutational burden tumors 
which may have more neoantigens like lung cancer and 
melanoma when they are treated with immune checkpoint 
inhibitors [2, 3].
This led to rapid advances in early phase clinical 
trials in many such tumor types. However, tumors with 
low mutational burden were left out without any real 
evidence of lack of PD-1/PD-L1 expression or efficacy. 
Figure 2 is adapted from a seminal paper from Nature 
Reviews and shows low mutational burden of well 
differentiated neuroendocrine tumors (carcinoid) [4].
The notion that low mutational burden predicts 
poor response to immune checkpoint inhibitors has 
come into question by some of the leading experts in 
immune-oncology. This could be due to three factors: 
Firstly, the data regarding PD-1/PD-L1 expression is 
expanding even in low mutational burden tumors [5, 24]. 
Secondly, there is growing evidence that PD-1/PDL-
1 expression is not static and can change with tumor 
progression and based on tumor microenvironment [6]. 
Lastly, PD-1/PD-L1 expression can be augmented with 
help of immunomodulators. In fact, the newer immune 
checkpoint inhibitor clinical trials are utilizing concurrent 
cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor, 
Indoleamine 2,3-dioxygenase inhibitors (IDO), interferon 
(INF), radiation and cytotoxic chemotherapy to enhance 
the efficacy of immune checkpoint inhibitors [7-10].
Immuno-oncology in neuroendocrine tumors
Oberg et al. were among the first researchers 
to report the potential benefit of interferon (INF) in 
neuroendocrine tumors. They treated 9 NET patients, 
including six with carcinoid syndrome, with daily 
intramuscular INF for three months. All six syndromic 
patients experienced temporary relief in carcinoid 
syndrome symptoms and concomitant decline in urinary 
5 HIAA levels [11].
Moertel et al. treated 27 of their neuroendocrine 
tumor patients with interferon. 24 out of 27 patients 
had carcinoid syndrome. 20% of the patients had an 
objective decrease in tumor size. 39% of functional NET 
patients experienced reduction in urinary 5 HIAA (>50%) 
levels. These effects were transient for about 4-7 weeks. 
Moreover, authors recommended against the use of INF 
due to toxic side-effects which included fever, fatigue, and 
weight loss [12].
In a subsequent prospective randomized clinical trial 
of octreotide (n = 35) versus octreotide with INF (n = 33) 
for metastatic midgut carcinoid tumor patients, a superior 
Table 1: Summary of immune checkpoint inhibitor experience in neuroendocrine tumors 
Patient Age Diagnosis Grade Treatment Prior Treatments Duration of Treatment Outcome
43 
Stage IV 
pNET, Non 
functional
II Pembrolizumab
somatostatin 
analog, sunitinib, 
capecitabine and 
temozolamide, 
everolimus and 
fosbretabulin
16 months
Progressed after 16 months 
of stable disease; Initially 
KPS increased from 60% to 
90%; 20 pound weight gain 
and enjoyed a good quality 
of life for over a year until 
progression. 
49
Stage IV NET 
of unknown 
primary, Non 
functional
II Nivolumab
somatostatin 
analogs, 
everolimus, 
capecitabine and 
temozolomide
6 months
KPS increased from 70% 
to 90% initially. Progressed 
after 6 months on treatment 
71
Stage IV 
pNET, Gastrin 
producing
I Nivolumab
somatostatin 
analog, 
everolimus, 
capecitabine and 
temozolomide, 
fosbretabulin
6 months Stable disease per imaging
75
Stage IV,
Bronchial 
NET, Non 
functional
I Pembrolizumab
Somatostatin 
analog, 
everolimus, XRT
3 months Stable disease per imaging
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progression free survival was evident for the combination 
arm; however, no significant difference was seen in overall 
survival [13].
Another randomized clinical trial done at around 
same time compared the efficacy of lanreotide (n = 25) to 
INF-alpha (n = 27) and the combination of lanreotide and 
INF-alpha (n = 28) in metastatic gastroenteropancreatic 
neuroendocrine tumor patients. The study concluded that 
the experimental agents had comparable anti-neoplastic 
activity in NETs but response rates were very poor. Only 
19 patients out of 80 showed stable disease at 12 months 
[14]. Arnold et al. prospectively studied interferon plus 
octreotide (n = 54) versus octreotide alone (n = 51) in 
105 gastroenteropancreatic tumor patients. The median 
survival was 54 months in the combination arm vs 32 
months in the octreotide only arm. The study could not 
establish superiority of the combination arm due to lack 
of statistical significance [15].
Based on the above mentioned weak evidence, 
marginal benefit and lack of therapeutic options, NCCN 
recommends (category 3) INF as one of the potential 
treatment choices for metastatic gastrointestinal and 
thoracic NET [16]. This recommendation fortunately has 
fallen off favor in general community practice. 
Table 2: Current status of Immune checkpoint inhibitor in prospective clinical trials for neuroendocrine tumors
NCT ID Disease cohort Investigational Agent Phase
Current 
Status
 Phase 2, Open-label Study of 
pembrolizumab monotherapy 
in Patients with Metastatic High 
Grade Neuroendocrine Tumors
02939651 Stage IV, G3 neuroendocrine tumor
Pembrolizumab
200mg every 3 weeks 2 Recruiting
Study of pembrolizumab 
With lanreotide Depot for 
Gastroenteropancreatic 
Neuroendocrine Tumors 
(PLANET)
03043664
Stage IV well or 
moderately differentiated 
gastroenteropancreatic 
neuroendocrine tumors 
(GEP-NETs)
Pembrolizumab 
200mg IV every 3 
weeks and Lanreotide 
depot 90mg SQ every 
3 weeks
1/2 Recruiting
Study of Efficacy and Safety 
of PDR001 in Patients with 
Advanced or Metastatic, Well-
differentiated, Non-functional 
Neuroendocrine Tumors of 
Pancreatic, Gastrointestinal 
(GI), or Thoracic Origin 
or Poorly-differentiated 
Gastroenteropancreatic 
Neuroendocrine Carcinoma 
(GEP-NEC)
02955069
Stage IV, Well differentiated 
non-functional NET of GI, 
Pancreas and Lungs
Poorly differentiated 
gastroenteropancreatic 
neuroendocrine carcinoma
PDR001 dose is 400 
mg infusion every 4 
weeks
PDR001 is a high-
affinity, ligand-
blocking, humanized 
IgG4 antibody 
directed against 
Programmed Death-1 
(PD-1) receptor that 
blocks the binding of 
PD-L1 and PD-L2. 
2 Recruiting
Pharmaco-immunological 
Study of Interferon-alpha and 
Metronomic Cyclophosphamide 
Association in Neuroendocrine 
Tumors (EPICentro)
02838342 Grade 1 or 2 metastatic neuroendocrine tumor
 Metronomic 
cyclophosphamide
Interferon-alpha
2 Recruiting
Study of JS001 in Patients with 
Advanced Neuroendocrine 
Tumors
 03167853
Stage IV, Grade 2 or 
3, well-differentiated 
neuroendocrine tumors and 
poorly-differentiated 
JS 001 humanized 
anti-PD-1 monoclonal 
antibody
1 Recruiting
Durvalumab (MEDI4736) plus 
tremelimumab for Advanced 
Neuroendocrine Neoplasms of 
Gastroenteropancreatic or Lung 
Origin (DUNE)
03095274
G1-2 GI, Pancreatic and 
Bronchial NET and G3 non-
thoracic neuroendocrine 
carcinoma. 
Durvalumab, 1500 
mg Q4W
Tremelimumab 75 mg 
Q4W
2 Recruiting
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Modern immuno-oncology and NETs
Ipilumumab, a monoclonal antibody against 
cytotoxic T lymphocyte antigen 4 (CTLA4), was approved 
in March 2011 and was the first immune checkpoint 
inhibitor to show an overall survival advantage in 
metastatic melanoma [17]. Theoretically, the efficacy 
of immune checkpoint inhibitors should be affected by 
the presence of tumor infiltrating lymphocytes (TILs). 
Increased TILs should in principle enhance the activity 
of anti-CTLA4 drugs. Although we have no direct 
prospective data on the efficacy of CTLA-4 agents in 
NETs, there is indirect data to suggest that immune 
checkpoint inhibitors might have activity in NETs. 
Ryschich et al. were the first to demonstrate the 
presence of CD3+ T cells in pancreatic neuroendocrine 
tumors (PNET) [18]. Later, a series published by Kat et al. 
from Memorial Sloan Kettering analyzed post-operative 
tumor specimens of 87 patients with primary PNET for 
TILs. They found a statistically significant difference in 
survival of intermediate grade (Ki 67 2-20%) PNET based 
on TIL density. Patients with dense T cell infiltration in 
tumor tissue had a median recurrence-free survival of 128 
months as compared to 62 months in the subset with low 
TILs (p = 0.05) [19].
Drug development for high grade NETs usually 
follows trends seen in small cell lung cancer, a pulmonary 
high grade NET. Reck et al. were among the first to study 
ipilumumab in extensive stage small cell lung cancer 
(SCLC). Phased ipilumumab with carboplatin/paclitaxel 
vs carboplatin/paclitaxel alone showed a statistically 
significant difference in irPFS (HR (hazard ratio) = 
0.64; p = 0.03). Although the improvement in irPFS did 
not translate into overall survival it was nevertheless 
indicative of drug efficacy in this tumor type [20]. 
Checkmate 032 evaluated nivolumab vs nivolumab 
plus ipilumumab in 128 SCLC patients who had 
progressed on prior platinum-based regimens. The overall 
response rate was 18% vs 32.6% for the combination arm 
[21]. The therapy showed significant antitumor activity, 
while maintaining durable responses and a manageable 
toxicity profile in patients with progressed SCLC. 
Keynote 028 evaluated pembrolizumab in PD-L1 positive 
progressive SCLC patients. Out of 24 treated patients one 
patient had complete response and 8 had partial response. 
ORR was 37.5% [28]. Whether these agents will prove to 
be effective in non-pulmonary high-grade NETs is yet to 
be seen. 
A recent retrospective study from Korea evaluated 
PD-L1 expression in metastatic gastroenteropancreatic 
(GEPNET) patients through immunohistochemical 
analysis. 7 out of 32 patient tumor tissues (21.9%) were 
found to be positive for PD-L1. Grade 3 GEPNETs were 
especially correlated with PD-L1 expression (p = 0.008) 
[22]. Additionally, the researchers found that patients 
expressing PD-L1 had a shorter progression-free survival 
time and a shorter overall survival. The presence of PD-
L1 was also linked to a higher tumor grade (grade 3) in 
metastatic GEPNETs. The presence of PD-L1 in these 
patients could act as a biomarker to predict survival. 
Figure 3: Gallium DOTATATE scan sowing disease burden at the time of progression on immune checkpoint inhibitor 
therapy (case 1)
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Ultimately, inhibition of PD-L1 could serve as a novel 
therapy for patients with metastatic GEPNETs. 
Leng et al. reported PD-L1 expression in 13 
out of 45 GI neuroendocrine tumor patients. PD-L1 
positive tumors were all poorly differentiated NETs [23]. 
Additionally, there was a significant correlation between 
the presence of PD-L1 expression and tumor grade. Cives 
et al. found 22 of their 32 GI NETs positive for PD-L1 
expression. Moreover, PD-L1 expression was related to 
worse outcomes as 5-year overall survival was 32% in 
PD-L1 positive patients versus 90% in PD-L1 negative 
patients [24].
Tsuruoka et al recently published their results on 
PD-L1 expression in thoracic neuroendocrine tumors. 
The authors conducted immunohistochemistry on tissue 
microarray with E1L3N, a PD-L1 antibody clone. The 
study samples were examined by two blinded independent 
investigators. A score of 1 or more was considered to be 
positive for PD-L1 expression. Out of 227 patients, 46 
were typical carcinoids (TC), 6 were atypical carcinoids 
(AC), 106 were large cell neuroendocrine carcinoma 
(LCNEC) and 69 were small cell lung carcinoma (SCLC). 
None of the TC and AC were found to be positive for PD-
L1 expression. 5.8% (n = 4) SCLC and 10.4% (n = 11) 
LCNEC patients were found PD-L1 positive [27]. It seems 
the PD-L1 expression is variable among neuroendocrine 
tumors and high grade neuroendocrine tumors might 
have higher odds of being PD-L1 positive especially 
gastroenteropancreatic origin. 
There have been two recent reports evaluating 
prognostic implication of PD-L1 and PD-1 expression in 
NETs. Fan et al. investigated 80 pulmonary neuroendocrine 
patients. 51.3% (41) patients had positive PD-1 expression 
in tumor infiltrating lymphocytes. A multivariate analysis 
of their study cohort revealed that both PD-1 and PD-L1 
expression were independent survival prognostic factors 
[29]. Kim et al studied prognostic implication of PD-
L1 expression in GEPNETs. 24 GEPNET patients were 
evaluated for PD-L1 expression and authors found that 
median overall survival in PD-L1 positive patients was 
16 months as compared to 24.8 months in PD-L1 negative 
patients [30]. 
Table 2 summarizes the ongoing clinical trials 
evaluating clinical activity of immune checkpoint 
inhibitors in neuroendocrine tumors. 
CONCLUSION
Specific clinical trials looking at just GEPNETs and 
immune checkpoint inhibitors are limited (Table 2) and 
although the results of these trials are still a few years 
away, it’s a step in right direction. Neuroendocrine tumors 
are an area of unmet medical need and despite increasing 
incidence and prevalence, the treatment options for 
progressive disease are limited. NET incidence has been 
rising over the past four decades. We recently presented 
our 18-year Kentucky Cancer Registry database review 
at a national neuroendocrine symposium and found multi-
fold increase in incidence of NETs from 3.76/100,000 to 
10.7/100,000 population [25]. This is consistent with the 
surge in incidence seen at the national level per SEER 
database [26]. As most decisions in drug development 
are affected by pharmacoeconomics, continued efforts 
from the medical fraternity exploring the role of immune 
checkpoint inhibitors in NETs might turn the tide. 
Our patients certainly benefited from a trial of 
immune checkpoint inhibitors without any adverse side 
effects. Overall, we were able to provide some degree of 
disease stabilization and improved performance status. It 
is to be noted that all our study patients had otherwise 
exhausted all standard of care treatment options and were 
on the verge of hospice. Our single center experience 
shows encouraging results. We eagerly await results of 
prospective clinical trials.
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